PharmacyCodes



Telmisartan [INN] en es it fr

Telmisartan [INN] Brand names, Telmisartan [INN] Analogs

Telmisartan [INN] Brand Names Mixture

  • No information avaliable

Telmisartan [INN] Chemical_Formula

C7H9ClO6P2S

Telmisartan [INN] RX_link

http://www.rxlist.com/cgi/generic2/tiludronate.htm

Telmisartan [INN] fda sheet

Telmisartan [INN] msds (material safety sheet)

Telmisartan [INN] Synthesis Reference

No information avaliable

Telmisartan [INN] Molecular Weight

318.609 g/mol

Telmisartan [INN] Melting Point

No information avaliable

Telmisartan [INN] H2O Solubility

No information avaliable

Telmisartan [INN] State

Solid

Telmisartan [INN] LogP

0.549

Telmisartan [INN] Dosage Forms

Tablets for oral administration containing 240 mg tiludronate disodium

Telmisartan [INN] Indication

For treatment of Paget's disease of bone (osteitis deformans).

Telmisartan [INN] Pharmacology

Tiludronate is a first generation (non-nitrogenous) bisphosphonate in the same family as etidronate and clodronate. Tiludronate affects calcium metabolism and inhibits bone resorption and soft tissue calcification. Of the tiludronate that is resorbed (from oral preparation) or infused (for intravenous drugs), about 50% is excreted unchanged by the kidney. The remainder has a very high affinity for bone tissue, and is rapidly absorbed onto the bone surface.

Telmisartan [INN] Absorption

The mean oral bioavailability in healthy male subjects is 6% after an oral dose equivalent to 400 mg tiludronic acid administered after an overnight fast and 4 hours before a standard breakfast. In single-dose studies, bioavailability was reduced by 90% when an oral dose equivalent to 400 mg tiludronic acid was administered with, or 2 hours after, a standard breakfast compared to the same dose administered after an overnight fast and 4 hours before a standard breakfast.

Telmisartan [INN] side effects and Toxicity

Based on the known action of tiludronate, hypocalcemia is a potential consequence of overdose. In one patient with hypercalcemia of malignancy, intravenous administration of high doses (800 mg/day total dose, 6 mg/kg/day for 2 days) was associated with acute renal failure and death.

Telmisartan [INN] Patient Information

Telmisartan [INN] Organisms Affected

Humans and other mammals